Clinical Commissioning Policy: Clinical Commissioning Policy:

First Page		Document Content
Date: 2014-08-12 08:05:41 Medicine Immunosuppressants Autoimmune diseases Neurological disorders Glatiramer acetate Natalizumab Fingolimod McDonald criteria Interferon Immunology Multiple sclerosis Immune system		Clinical Commissioning Policy: Clinical Commissioning Policy: Add to Reading List Source URL: www.england.nhs.uk Download Document from Source Website File Size: 523,92 KB Share Document on Facebook

	20th NSW Stem Cell Network Workshop - in collaboration with MS Research Australia Stem Cells in Multiple Sclerosis and Neurological Disease DocID: 1vbZP - View Document
	Insights into Type 1 Diabetes and Multiple Sclerosis Pathogenesis from Common Genetic Associations Sandeep K. Singh 1, Aziz A. Chentoufi 2, Jacob L. McCauley 3, Mehmet Tevfik Dorak 4 1Florida DocID: 1vaUi - View Document
	Cigarette Smoking and Incidence of Multiple Sclerosis -- Heman et al): 69 -- Ame...Page 1 of 14 Oxford Journals • ContactUs ...... DocID: 1v0yh - View Document
	MULTIPLE SCLEROSIS Clues to its cause URI LEIBOWITZ Department of Neurology, Hadassah University Hospital and Hebrew U+riversity-Hada.ssah Medical School, DocID: 1uW5T - View Document
	CNS Vital Signs Advancing Multiple Sclerosis Care Adding Value to Your Practice by Providing Solutions for Measuring, Monitoring and Managing Neurocognitive and Behavioral Health… www.CNSVS.com DocID: 1uFcb - View Document